Memoirs

The master builder CEO leading Codis Nick Fortin’s story is one of curiosity, courage and continuous improvement. From his beginnings in Montreal’s manufacturing scene to becoming CEO of Codis, Nick’s journey shows what can happen when you keep learning, keep building and never stop pushing yourself. When I sat down with Nick, I walked away …

From R&D to CRO CEO Dr. Fozia Saleem’s journey from R&D scientist to CEO is as fascinating as it is inspiring. After years in global roles at GSK, BAT, and Broughton, she now leads Magnitude Biosciences — a scrappy, fast-moving CRO helping clients generate better data, earlier, through its WormGazer® technology platform. When I sat …

The CEO driving bold change at PathoQuest Jean-François Brepson spent 20 years climbing the ladder at Ipsen before making the leap from the security of corporate pharma into the messy, uncertain world of entrepreneurship. Since 2015, he has led PathoQuest and transformed it into a global CRO specialising in quality control of biologics using Next …

The CEO leading Ensera’s evolution Jason Anderson has taken a fascinating route to the CEO chair at Ensera. From chemical engineering at BASF, to McKinsey, to a venture backed polymer start up sold to Saudi Aramco, he has lived and worked across North America, Asia, and Europe. Today he is leading Ensera (formerly SteriPack) through …

The understated CDMO CCO JB Agnus has built a career that spans global roles at some of the biggest names in pharma services. Today, he is Chief Commercial Officer at Bora Pharmaceuticals, helping drive the company’s remarkable trajectory in the CDMO space. When I sat down with JB, here is what I took away: What …

The CEO driving change at Curia Phil Macnabb has over 25 years of working with private equity, and more than a decade in healthcare. Today he is steering Curia, a billion plus revenue CDMO, through some tough but necessary changes. When I sat down with Phil, I walked away with three big lessons: What I …

Lars Petersen’s story is one of purpose, grit and quiet conviction. After 25 years in big pharma with Novo Nordisk, Genentech, Roche and Biogen, he now leads FUJIFILM Biotechnologies, shaping a global CDMO known as much for its culture and innovation as for its scale. The People first CEO of FUJIFILM Biotechnologies When I sat …

Forty years. Six exits. And still not ready to hang up the boots. When I sat down with Adam Sherlock, CEO at Qinecsa, I came away with three big lessons: What I liked about Adam: he’s a genuinely lovely guy — friendly, kind, generous, and wonderfully understated considering his track record. What I admire most is …

The challenger changing how pharma thinks about digital Matt Lowe is a force of nature. After two decades in the pharmaceutical world, he spotted a glaring blind spot in how the industry approaches search, customer experience and digital marketing. So he left big pharma, built Performance.io from the ground up, and set out to challenge …

Doc to CEO – 40 years of reinvention in biopharma Every now and then you meet someone whose career just blows you away — not just for what they’ve achieved, but for how grounded they are about it. Dr Stephen Dilly has spent almost 40 years in the biopharma industry and 20 of those as …